Search

Background. Recent experimental and clinical studies have confirmed the effectiveness and safety of serratiopeptidase (SRP) as a powerful anti-inflammatory agent, highlighting its potential benefits across various fields of medicine. The purpose was to analyze current literature on the mechanisms of action of SRP as a means of systemic enzyme therapy for low-intensity chronic inflammation and pain syndromes, its clinical applications, and prospects for implementation in general medical practice. Materials and methods. To identify relevant literature sources, a comprehensive search was conducted in electronic databases, including PubMed, Scopus, Web of Science, and the Cochrane Library. Results. According to modern literature data, SRP demonstrates quite powerful anti-inflammatory, analgesic, reparative, fibrinolytic, and mucolytic properties, and exhibits a certain antimicrobial activity, especially against biofilm-forming bacteria. The combination of this enzyme with traditional antibiotics provides a more effective treatment of infectious processes. SRP has significant potential in the treatment of conditions and diseases associated with the development of low-intensity chronic inflammation and pain syndromes (especially in comorbid ones) due to its anti-inflammatory, anti-edematous, antithrombotic, and analgesic properties associated with the inhibition of cyclooxygenase 1 and 2, 5-lipoxygenase activity, myeloperoxidase and elastase, suppression of the formation and/or release of bradykinin, biogenic amines, pro-inflammatory cytokines, cell adhesion molecules, cleavage of bradykinin- related peptides, limitation of oxidative-nitrosative stress. The effectiveness of the enzyme notably increases when it is combined with some prebiotics and/or probiotics. Conclusions. The development of new dosage forms of SRP, along with further preclinical and clinical trials, could lead to new strategies for the prevention and treatment of inflamatory diseases. [ABSTRACT FROM AUTHOR]

The modern treatment strategy for various forms of generalized periodontitis includes the use of a wide arsenal of drugs, which in turn leads to an excessive drug load on the body, this actualizes the search and use of drugs that have a systemic effect. The aim of the study is to develop and study the effectiveness of the use of systemic enzyme therapy in the treatment of aggressive (rapidly progressing) generalized periodontitis. The work is based on the results of comprehensive clinical and laboratory studies of 61 patients with an aggressive form of generalized periodontitis, without concomitant pathologies (30 main groups and 31 comparison groups). A control group consisted of 20 healthy donor volunteers. We used standard clinical, paraclinical, laboratory diagnostic methods, supplemented by dental volumetric tomography. In patients of both observation groups, standard protocol therapy was used, in the comparison group supplemented pathogenic therapy, and in the main group – multienzyme drug (Wobenzym) and rhBMP-2 injections. A comparative analysis of clinical, paraclinical, and laboratory studies has shown that the use of systemic enzyme therapy supplemented with recombinant morphogenetic protein (rhBMP-2) in patients with aggressive (rapidly progressing) generalized periodontitis is comparable to that of standard polymedicine therapy supplemented with pathogenic therapy, and leads to a faster control (average 13.7±0.7 days) of an active inflammatory and destructive process, normalization of indices of local humoral immunity, cytokine profile, free radical oxidation and antioxidant defense system, achievement of clinical and radiological remission in more than 90% of patients. [ABSTRACT FROM AUTHOR]

In this presented report female patients suffering from carpal tunnel syndromes were examined. The disorders were detected during the preventive occupational examinations. Median nerve lesions were detected 11 times in 6 electro-winders (risk of the long-term one-sided overloading, category No. 3) with electromyographic examination. Distinct subjective symptoms relief occurred after 6 weeks of treatment with Wobenzym in most cases. During a control examination 6 weeks after the cessation of treatment with Wobenzym the healing effect lasted. The electromyographic examination after 6 weeks of treatment confirmed the distal motor latency improvement in 8 out of 9 cases. 6 weeks after ceasing the treatment the improvement of the distal motor latency lasted in 7 out of 9 cases. Changes in the velocity of sensitive conduction were not unambiguous. On the basis of these and previously documented experiences a systemic therapy may be considered as a therapeutic modality extending the list of conservative treatment of the carpal tunnel syndrome methods or as a component of preventive beneficiary programs. However, verification in a more extensive study is desirable. [ABSTRACT FROM AUTHOR]